Physician profile
Mark W Evans
NPI 1457571325
$455.74
in general payments reported to CMS, 2019-2025
13 companies · $56.09 in 2025
The $56.09 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $61.59 · 2021: $12.08 · 2022: $20.24 · 2023: $34.65 · 2024: $151 · 2025: $56.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $99.96 | 2019-2024 | |
| Smith+Nephew, INC. | $90.66 | 2019-2025 | Grafix |
| Janssen Pharmaceuticals, INC | $40.69 | 2022-2024 | Xarelto |
| Integra Lifesciences Corporation | $34.23 | 2019-2023 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Urgo Medical North America, LLC | $32.09 | 2024-2025 | Urgok2 |
| Mozarc Medical US LLC | $31.43 | 2024 | Palindrome |
| Kci USA, INC. | $26.50 | 2019 | |
| Polynovo North America LLC | $23.55 | 2024 | Novosorb Btm |
| Melinta Therapeutics, LLC | $18.92 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.17 | 2023 | Seglentis |
| Avanos Medical | $14.84 | 2019 | |
| Solventum Corporation | $14.01 | 2025 | Activ.A.C. |
| Merck Sharp & Dohme LLC | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.